Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2026)

Aquestive Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $110.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 61.29% year-over-year to $110.7 million in Q1 2026; TTM through Mar 2026 was $110.7 million, a 61.29% increase from a year earlier, with the FY2025 full-year figure at $121.2 million, up 69.36% from the prior year.
• Cash & Equivalents slipped to $110.7 million in Q1 2026 per AQST's latest filing, from $121.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $129.1 million in Q3 2025 and bottomed at $14.7 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $60.5 million (2025), against an average of $58.9 million.
• Across the five-year window, Cash & Equivalents tumbled 48.31% in 2022 and surged 300.56% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $27.3 million in 2022, then dropped by 12.47% to $23.9 million in 2023, then surged by 199.71% to $71.5 million in 2024, then surged by 69.36% to $121.2 million in 2025, then dropped by 8.61% to $110.7 million in 2026.
• Per Business Quant, the three latest AQST Cash & Equivalents figures stand at $110.7 million (Q1 2026), $121.2 million (Q4 2025), and $129.1 million (Q3 2025).